ACT's Phase 1/2 Program for Retinal Degeneration

ACT has developed a human embryonic stem cell-based therapy that without destroying the embryo, uses retinal pigment epithelial (RPE) cells to treat a variety of blindness-causing retinal degenerative diseases.

ACT's Phase 1/2 clinical program consists of two trials to assess the safety and tolerability of RPE cell therapy, one in patients with Stargardt's disease (juvenile macular degeneration) and the other in dry age-related macular degeneration (Dry AMD).

For more information on ACT's Phase 1/2 human clinical trial for Stargardt's Macular Dystrophy (SMD), CLICK HERE.

For more information on ACT's Phase 1/2 human clinical trial for Dry Age-Related Macular Degeneration (Dry AMD), CLICK HERE.

For more information about the first human clinical data published for ACT’s ongoing clinical trials, CLICK HERE.